Latest News
Odyssey Therapeutics, Inc.
- Odyssey Therapeutics reports phase 2a ulcerative colitis trial data By Investing.com
- Odyssey Therapeutics reports phase 2a ulcerative colitis trial data By Investing.com
- Odyssey Therapeutics Reports Positive Phase 2a Ulcerative Colitis Data for Oral OD-001, Supporting Further Development
- Odyssey Therapeutics Presents Completed Phase 2a OD-001
- Odyssey Therapeutics reports positive Phase 2a results for OD-001 in ulcerative colitis, advancing to Phase 2b trials.
- UBS initiates Odyssey Therapeutics stock with buy rating on IBD drug
- Odyssey Therapeutics to Present Design of Phase 2a Study
- Odyssey Therapeutics Initiated at Buy by UBS
- Odyssey Therapeutics to present phase 2a trial design for UC By Investing.com
- Raymond James initiates Odyssey Therapeutics stock coverage with outperform rating
Headlines from the last 30 days, linking to the original publishers. See all market news →